MCID: SCN036
MIFTS: 53

Secondary Progressive Multiple Sclerosis

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Secondary Progressive Multiple Sclerosis

MalaCards integrated aliases for Secondary Progressive Multiple Sclerosis:

Name: Secondary Progressive Multiple Sclerosis 12 56 15 17
Multiple Sclerosis, Secondary Progressive 74
Multiple Sclerosis, Chronic Progressive 45
Chronic Progressive Multiple Sclerosis 17
Secondary-Progressive Ms 12
Spms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050783
MeSH 45 D020528
UMLS 74 C0751965

Summaries for Secondary Progressive Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterised by a worsening of disability, rather than by relapses followed by recovery, which progressively worsens until a steady progression of disability replaces the cycles of attacks.

MalaCards based summary : Secondary Progressive Multiple Sclerosis, also known as multiple sclerosis, secondary progressive, is related to multiple sclerosis and encephalitis. An important gene associated with Secondary Progressive Multiple Sclerosis is HNRNPA1 (Heterogeneous Nuclear Ribonucleoprotein A1), and among its related pathways/superpathways are PEDF Induced Signaling and Akt Signaling. The drugs 4-Aminopyridine and Dimethyl fumarate have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and b cells, and related phenotypes are cellular and behavior/neurological

Related Diseases for Secondary Progressive Multiple Sclerosis

Diseases in the Multiple Sclerosis family:

Multiple Sclerosis 2 Multiple Sclerosis 3
Multiple Sclerosis 4 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis

Diseases related to Secondary Progressive Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
# Related Disease Score Top Affiliating Genes
1 multiple sclerosis 30.1 CCL2 CCR5 CXCL10 CXCR3 IFNB1 IFNG
2 encephalitis 30.0 CCL2 CCR5 CXCL10
3 primary progressive multiple sclerosis 30.0 IFNB1 IL10 MBP MMP9 S100B
4 arthritis 29.8 CCL2 IFNG IL10 MMP9
5 relapsing-remitting multiple sclerosis 29.4 HNRNPA1 IFNB1 IFNG IL10 MBP MMP9
6 scapuloperoneal myopathy, x-linked dominant 11.9
7 degos 'en cocarde' erythrokeratoderma 10.7
8 lentigo maligna melanoma 10.4 MMP9 S100B
9 intracranial cysts 10.4 ENO2 S100B
10 acute transverse myelitis 10.4 IL10 MMP9
11 bednar tumor 10.4 ENO2 S100B
12 epithelioid malignant peripheral nerve sheath tumor 10.4 ENO2 S100B
13 finger agnosia 10.4 ENO2 MBP
14 ossifying fibromyxoid tumor 10.4 ENO2 S100B
15 folliculotropic mycosis fungoides 10.4 CCR3 CXCR3
16 retroperitoneal neuroblastoma 10.4 ENO2 IFNB1
17 niemann-pick disease 10.3
18 epilepsy 10.3
19 diabetic foot ulcers 10.3 CCL2 MMP9
20 palladium allergic contact dermatitis 10.3 CCL2 IL10
21 chromoblastomycosis 10.3 CXCR3 MMP9
22 head injury 10.3 ENO2 S100B
23 transverse myelitis 10.3 IL10 MBP MMP9
24 temporal lobe epilepsy 10.3
25 bacterial meningitis 10.3 IL10 MMP9 S100B
26 appendicitis 10.3 ENO2 IL10 MMP9
27 balo concentric sclerosis 10.3 IFNB1 MBP
28 cephalosporin allergy 10.3 IFNG IL10
29 optic nerve glioma 10.3 ENO2 MBP S100B
30 cerebral primitive neuroectodermal tumor 10.3 ENO2 IFNB1 S100B
31 allergic encephalomyelitis 10.3 CXCL10 MBP
32 mucocutaneous leishmaniasis 10.3 CCR5 IL10
33 opsoclonus-myoclonus syndrome 10.3 CXCL10 CXCR3
34 hyperlucent lung 10.3 IFNG IL10
35 middle cerebral artery infarction 10.3 CD40LG ENO2 S100B
36 neurosyphilis 10.2 CXCL10 IL10
37 tuberculous meningitis 10.2 CCL2 ENO2 MMP9
38 meningeal melanocytoma 10.2 CD40LG ENO2 S100B
39 acrodermatitis chronica atrophicans 10.2 CD40LG CXCL10
40 extrinsic allergic alveolitis 10.2 CCL2 CXCR3 IL10
41 ocular toxoplasmosis 10.2 CCR5 CD40LG
42 dementia 10.2
43 kawasaki disease 10.2 CCL2 IL10 MMP9
44 nickel allergic contact dermatitis 10.2 IFNG IL10
45 oligodendroglioma 10.2 ENO2 MBP S100B
46 extrinsic cardiomyopathy 10.2 CCL2 IFNB1 IL10
47 scleritis 10.2 IFNG MMP9
48 baylisascariasis 10.2 IFNG IL10
49 pelvic inflammatory disease 10.2 CCL2 CD40LG MMP9
50 pneumonia 10.2 CCL2 CD40LG IL10

Graphical network of the top 20 diseases related to Secondary Progressive Multiple Sclerosis:



Diseases related to Secondary Progressive Multiple Sclerosis

Symptoms & Phenotypes for Secondary Progressive Multiple Sclerosis

MGI Mouse Phenotypes related to Secondary Progressive Multiple Sclerosis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.15 CCR3 CCR5 CD40LG CXCL10 CXCR3 ENO2
2 behavior/neurological MP:0005386 10.06 CCR5 ENO2 IFNG IL10 MBP MMP9
3 hematopoietic system MP:0005397 10.06 CCR3 CCR5 CD40LG CXCL10 CXCR3 IFNB1
4 homeostasis/metabolism MP:0005376 10.03 CCR3 CCR5 CD40LG CXCL10 CXCR3 IFNB1
5 immune system MP:0005387 9.93 CCL2 CCR3 CCR5 CD40LG CXCL10 CXCR3
6 neoplasm MP:0002006 9.5 CCR5 CXCR3 IFNB1 IFNG IL10 MMP9
7 nervous system MP:0003631 9.32 CCR5 CD40LG CXCL10 ENO2 IFNB1 IFNG

Drugs & Therapeutics for Secondary Progressive Multiple Sclerosis

Drugs for Secondary Progressive Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 181)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
4-Aminopyridine Approved Phase 4,Phase 3 504-24-5 1727
2
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3 624-49-7 5271565 637568
3
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2 145155-23-3
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5 Hormones Phase 4,Phase 2,Phase 3,Phase 1
6 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
7 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
9 Potassium Channel Blockers Phase 4,Phase 3
10 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1
11 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1
12 Immunosuppressive Agents Phase 4,Phase 2,Phase 3
13 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
14 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1
15
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 83-43-2 6741
16
Histamine Approved, Investigational Phase 2, Phase 3 51-45-6 774
17
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
18
rituximab Approved Phase 2, Phase 3,Phase 1 174722-31-7 10201696
19
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 302-25-0
20
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3,Phase 3,Phase 1 2921-57-5
21
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
22
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 50-24-8 5755
23
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
24
Simvastatin Approved Phase 3,Phase 2 79902-63-9 54454
25
Natalizumab Approved, Investigational Phase 3,Phase 2,Phase 1 189261-10-7
26
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
28
Prednisolone hemisuccinate Experimental Phase 2, Phase 3,Phase 3,Phase 1 2920-86-7
29 Antirheumatic Agents Phase 2, Phase 3,Phase 3,Phase 1
30 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 3,Phase 1
31 Analgesics Phase 3,Phase 1,Phase 2
32 Anti-Infective Agents Phase 3,Phase 1,Phase 2
33 Antiviral Agents Phase 3,Phase 1,Phase 2
34 Neurotransmitter Agents Phase 2, Phase 3,Phase 1
35 Prednisolone acetate Phase 2, Phase 3,Phase 3,Phase 1
36 Anti-Allergic Agents Phase 2, Phase 3
37 Gastrointestinal Agents Phase 2, Phase 3,Phase 3,Phase 1
38 (T,G)-A-L Phase 2, Phase 3
39 Protective Agents Phase 2, Phase 3,Phase 3,Phase 1
40 Histamine H1 Antagonists Phase 2, Phase 3
41 Antiemetics Phase 2, Phase 3,Phase 3,Phase 1
42 Liver Extracts Phase 2, Phase 3
43
Chlorpheniramine Phase 2, Phase 3 113-92-8, 132-22-9 2725
44
Glatiramer Acetate Phase 2, Phase 3 147245-92-9 3081884
45 Antipruritics Phase 2, Phase 3
46 Adjuvants, Immunologic Phase 2, Phase 3,Phase 3,Not Applicable
47 Methylprednisolone Acetate Phase 2, Phase 3,Phase 3,Phase 1
48 Autonomic Agents Phase 2, Phase 3,Phase 3,Phase 1
49 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 1
50 Neuroprotective Agents Phase 2, Phase 3,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 89)
# Name Status NCT ID Phase Drugs
1 A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Completed NCT02208050 Phase 4 Fampridine;Placebo
2 Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers Completed NCT02683863 Phase 4 BG00012 (DMF) (Tecfidera®.)
3 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
4 BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Completed NCT03269175 Phase 4
5 Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for Multiple Sclerosis (MS) Not yet recruiting NCT03961204 Phase 4 Cladribine
6 Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis Terminated NCT01411514 Phase 4 Prednisone;Placebo
7 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis Unknown status NCT02220244 Phase 3 MD1003 100mg capsule
8 Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients Completed NCT03315923 Phase 2, Phase 3 Rituximab;Glatiramer Acetate
9 A Study for Patients With Secondary Progressive Multiple Sclerosis Completed NCT00869726 Phase 2, Phase 3 dirucotide;Placebo
10 Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis Completed NCT00241254 Phase 3 Cyclophosphamide (drug);Methylprednisolone (drug)
11 Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) Completed NCT01188811 Phase 2, Phase 3 lipoic acid;Placebo
12 A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis Completed NCT01917019 Phase 3 Placebo;BIIB041 (fampridine)
13 Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP) Recruiting NCT03653273 Phase 3 DMT continuation
14 Multiple Sclerosis-Simvastatin Trial 2 Recruiting NCT03387670 Phase 3 Simvastatin;Placebo
15 Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) Active, not recruiting NCT01665144 Phase 3 BAF312;Placebo
16 Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis Active, not recruiting NCT01433497 Phase 3 Masitinib;Placebo
17 A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis Terminated NCT01416181 Phase 3 natalizumab;Placebo
18 Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT00468611 Phase 3 MBP8298
19 BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis Terminated NCT02430532 Phase 3 dimethyl fumarate
20 Study Evaluating Mitoxantrone in Multiple Sclerosis Terminated NCT00146159 Phase 3 Mitoxantrone
21 A Study for Patients With Multiple Sclerosis Terminated NCT00870155 Phase 2, Phase 3 dirucotide
22 Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS) Withdrawn NCT00313976 Phase 3 Interferon beta-1b (Betaferon/Betaseron, BAY86-5046);Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
23 AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2 Hyperimmune caprine serum against HIV lysate
24 Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition Unknown status NCT01466114 Phase 2 estriol;Norethindrone
25 Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Unknown status NCT02273635 Phase 1, Phase 2 Andrographolides;placebo
26 Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis Completed NCT02228213 Phase 2 Saline
27 A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis Completed NCT00257855 Phase 2 Lamotrigine
28 Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis Completed NCT00647348 Phase 2 Simvastatin;Placebo
29 Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis Completed NCT01450488 Phase 2 masitinib;masitinib
30 Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis Completed NCT01684761 Phase 2
31 Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis Completed NCT01056471 Phase 1, Phase 2
32 Natalizumab Treatment of Progressive Multiple Sclerosis Completed NCT01077466 Phase 2 Natalizumab
33 Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Completed NCT00342134 Phase 2
34 Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Completed NCT01982942 Phase 2 ibudilast;Placebo oral capsule
35 Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis Completed NCT01191996 Phase 1, Phase 2
36 Treatment of Multiple Sclerosis Using Over the Counter Inosine Completed NCT00067327 Phase 2 Inosine
37 Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS) Completed NCT00086671 Phase 2 ABT-874/Human monoclonal antibody against IL-12;Placebo
38 A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) Completed NCT00436826 Phase 2 Cladribine;Placebo;Interferon-beta (IFN-beta)
39 Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis Completed NCT01517282 Phase 1, Phase 2
40 Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis Completed NCT00587691 Phase 1, Phase 2
41 Domperidone in Secondary Progressive Multiple Sclerosis (SPMS) Recruiting NCT02308137 Phase 2 Domperidone
42 Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease Recruiting NCT02649985 Phase 1, Phase 2 [F-18]PBR06
43 ACTH in Progressive Forms of MS Recruiting NCT01950234 Phase 2 ACTH;Placebo
44 A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients Recruiting NCT03560739 Phase 2 OMB157
45 Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis Recruiting NCT02988401 Phase 1, Phase 2 Insulin;Placebo (Sterile diluent)
46 MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial Active, not recruiting NCT01910259 Phase 2 Amiloride;Riluzole;Fluoxetine;Placebo
47 Autologous Mesenchymal Stromal Cells for Multiple Sclerosis Active, not recruiting NCT02495766 Phase 1, Phase 2 XCEL-MC-ALPHA;Placebo
48 Simvastatin in Secondary Progressive Multiple Sclerosis Not yet recruiting NCT03896217 Phase 2 Simvastatin
49 Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS Not yet recruiting NCT03696485 Phase 1, Phase 2
50 Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe) Terminated NCT01212094 Phase 1, Phase 2 Rituximab

Search NIH Clinical Center for Secondary Progressive Multiple Sclerosis

Cochrane evidence based reviews: multiple sclerosis, chronic progressive

Genetic Tests for Secondary Progressive Multiple Sclerosis

Anatomical Context for Secondary Progressive Multiple Sclerosis

MalaCards organs/tissues related to Secondary Progressive Multiple Sclerosis:

42
Brain, T Cells, B Cells, Spinal Cord, Cortex, Thyroid, Myeloid

Publications for Secondary Progressive Multiple Sclerosis

Articles related to Secondary Progressive Multiple Sclerosis:

(show top 50) (show all 277)
# Title Authors Year
1
Cervical dystonia in a case of longstanding secondary progressive multiple sclerosis. ( 30612702 )
2019
2
Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis. ( 31094285 )
2019
3
Can We Treat Secondary Progressive Multiple Sclerosis Now? ( 31007422 )
2019
4
Secondary progressive multiple sclerosis and the gut-brain axis. ( 30946474 )
2019
5
Magnetisation transfer ratio abnormalities in primary and secondary progressive multiple sclerosis. ( 30957691 )
2019
6
Multiple challenges for people after transitioning to secondary progressive multiple sclerosis: a qualitative study. ( 30852548 )
2019
7
Cognitive speed and white matter integrity in secondary progressive multiple sclerosis. ( 30802808 )
2019
8
Increased level of fibrinogen chains in the proteome of blood platelets in secondary progressive multiple sclerosis patients. ( 30838756 )
2019
9
Gut microbiota-dependent CCR9+CD4+ T cells are altered in secondary progressive multiple sclerosis. ( 30770703 )
2019
10
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. ( 30644981 )
2019
11
Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis. ( 30615019 )
2019
12
High-frequency repetitive transcranial magnetic stimulation and intermittent theta-burst stimulation for spasticity management in secondary progressive multiple sclerosis. ( 30472778 )
2019
13
Siponimod for the treatment of secondary progressive multiple sclerosis. ( 30517042 )
2019
14
Olfactory function and cognition in relapsing-remitting and secondary-progressive multiple sclerosis. ( 30273697 )
2019
15
Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort. ( 29111873 )
2019
16
Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis. ( 30477834 )
2018
17
Integration of magnetic resonance imaging and protein and metabolite CSF measurements to enable early diagnosis of secondary progressive multiple sclerosis. ( 30214633 )
2018
18
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. ( 30166303 )
2018
19
Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies. ( 30090637 )
2018
20
Prospects of siponimod in secondary progressive multiple sclerosis. ( 30038666 )
2018
21
Progressive visual function impairment as the predominant symptom of the transition phase to secondary progressive multiple sclerosis: A case report. ( 29957351 )
2018
22
Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview. ( 29968175 )
2018
23
Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. ( 29768414 )
2018
24
Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study. ( 29846780 )
2018
25
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. ( 29545067 )
2018
26
Natalizumab in secondary progressive multiple sclerosis. ( 29545068 )
2018
27
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. ( 29576505 )
2018
28
Balance Right in Multiple Sclerosis (BRiMS): a guided self-management programme to reduce falls and improve quality of life, balance and mobility in people with secondary progressive multiple sclerosis: a protocol for a feasibility randomised controlled trial. ( 28770099 )
2018
29
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. ( 28396953 )
2017
30
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. ( 27003945 )
2017
31
Identification of galectin-3 as a possible antibody target for secondary progressive multiple sclerosis. ( 27339072 )
2017
32
Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis. ( 27620894 )
2017
33
The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals. ( 27685028 )
2017
34
Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis? ( 27753181 )
2017
35
Efficacy and safety of mitoxantrone use in primary and secondary progressive multiple sclerosis - study site experience based on the therapy of 104 patients. ( 27919195 )
2017
36
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. ( 28045953 )
2017
37
Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis. ( 28145395 )
2017
38
Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis. ( 28429241 )
2017
39
Markers of oxidative/nitrative damage of plasma proteins correlated with EDSS and BDI scores in patients with secondary progressive multiple sclerosis. ( 28521618 )
2017
40
Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. ( 28572730 )
2017
41
To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question. ( 28594298 )
2017
42
Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. ( 28600189 )
2017
43
Corpus callosum atrophy as a marker of clinically meaningful cognitive decline in secondary progressive multiple sclerosis. Impact on employment status. ( 28601572 )
2017
44
Immune responses against Helicobacter pylori-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis. ( 28801580 )
2017
45
Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy. ( 28838904 )
2017
46
Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. ( 28905255 )
2017
47
Urinary Excretion of Aluminium and Silicon in Secondary Progressive Multiple Sclerosis. ( 29128442 )
2017
48
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date. ( 29138536 )
2017
49
Evaluation of neurological changes in secondary progressive multiple sclerosis patients treated with immune modulator MIS416: results from a feasibility study. ( 29177070 )
2017
50
Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient. ( 27430119 )
2016

Variations for Secondary Progressive Multiple Sclerosis

ClinVar genetic disease variations for Secondary Progressive Multiple Sclerosis:

6 (show all 38)
# Gene Variation Type Significance SNP ID Assembly Location
1 HNRNPA1 NM_002136.3(HNRNPA1): c.787T> C (p.Phe263Leu) single nucleotide variant Likely pathogenic rs483353022 GRCh37 Chromosome 12, 54677631: 54677631
2 HNRNPA1 NM_002136.3(HNRNPA1): c.787T> C (p.Phe263Leu) single nucleotide variant Likely pathogenic rs483353022 GRCh38 Chromosome 12, 54283847: 54283847
3 HNRNPA1 NM_002136.3(HNRNPA1): c.793A> G (p.Asn265Asp) single nucleotide variant Likely pathogenic rs483353023 GRCh37 Chromosome 12, 54677637: 54677637
4 HNRNPA1 NM_002136.3(HNRNPA1): c.793A> G (p.Asn265Asp) single nucleotide variant Likely pathogenic rs483353023 GRCh38 Chromosome 12, 54283853: 54283853
5 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> C (p.Phe273Leu) single nucleotide variant Pathogenic rs483353028 GRCh37 Chromosome 12, 54677661: 54677661
6 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> C (p.Phe273Leu) single nucleotide variant Pathogenic rs483353028 GRCh38 Chromosome 12, 54283877: 54283877
7 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> G (p.Phe273Val) single nucleotide variant Pathogenic rs483353028 GRCh37 Chromosome 12, 54677661: 54677661
8 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> G (p.Phe273Val) single nucleotide variant Pathogenic rs483353028 GRCh38 Chromosome 12, 54283877: 54283877
9 HNRNPA1 NM_002136.3(HNRNPA1): c.823C> T (p.Pro275Ser) single nucleotide variant Likely pathogenic rs483353029 GRCh37 Chromosome 12, 54677667: 54677667
10 HNRNPA1 NM_002136.3(HNRNPA1): c.823C> T (p.Pro275Ser) single nucleotide variant Likely pathogenic rs483353029 GRCh38 Chromosome 12, 54283883: 54283883
11 HNRNPA1 NM_002136.3(HNRNPA1): c.831G> T (p.Lys277Asn) single nucleotide variant Likely pathogenic rs483353030 GRCh37 Chromosome 12, 54677675: 54677675
12 HNRNPA1 NM_002136.3(HNRNPA1): c.831G> T (p.Lys277Asn) single nucleotide variant Likely pathogenic rs483353030 GRCh38 Chromosome 12, 54283891: 54283891
13 HNRNPA1 NM_002136.3(HNRNPA1): c.841T> C (p.Phe281Leu) single nucleotide variant Pathogenic rs483353031 GRCh37 Chromosome 12, 54677685: 54677685
14 HNRNPA1 NM_002136.3(HNRNPA1): c.841T> C (p.Phe281Leu) single nucleotide variant Pathogenic rs483353031 GRCh38 Chromosome 12, 54283901: 54283901
15 HNRNPA1 NM_002136.3(HNRNPA1): c.850A> G (p.Arg284Gly) single nucleotide variant Likely pathogenic rs483353032 GRCh37 Chromosome 12, 54677694: 54677694
16 HNRNPA1 NM_002136.3(HNRNPA1): c.850A> G (p.Arg284Gly) single nucleotide variant Likely pathogenic rs483353032 GRCh38 Chromosome 12, 54283910: 54283910
17 HNRNPA1 NM_002136.3(HNRNPA1): c.853A> G (p.Ser285Gly) single nucleotide variant Likely pathogenic rs483353033 GRCh37 Chromosome 12, 54677697: 54677697
18 HNRNPA1 NM_002136.3(HNRNPA1): c.853A> G (p.Ser285Gly) single nucleotide variant Likely pathogenic rs483353033 GRCh38 Chromosome 12, 54283913: 54283913
19 HNRNPA1 NM_002136.3(HNRNPA1): c.884A> G (p.Tyr295Cys) single nucleotide variant Likely pathogenic rs483353034 GRCh37 Chromosome 12, 54677728: 54677728
20 HNRNPA1 NM_002136.3(HNRNPA1): c.884A> G (p.Tyr295Cys) single nucleotide variant Likely pathogenic rs483353034 GRCh38 Chromosome 12, 54283944: 54283944
21 HNRNPA1 NM_002136.3(HNRNPA1): c.886T> C (p.Phe296Leu) single nucleotide variant Likely pathogenic rs483353035 GRCh37 Chromosome 12, 54677730: 54677730
22 HNRNPA1 NM_002136.3(HNRNPA1): c.886T> C (p.Phe296Leu) single nucleotide variant Likely pathogenic rs483353035 GRCh38 Chromosome 12, 54283946: 54283946
23 HNRNPA1 NM_002136.3(HNRNPA1): c.896C> T (p.Pro299Leu) single nucleotide variant Likely pathogenic rs483353036 GRCh37 Chromosome 12, 54677740: 54677740
24 HNRNPA1 NM_002136.3(HNRNPA1): c.896C> T (p.Pro299Leu) single nucleotide variant Likely pathogenic rs483353036 GRCh38 Chromosome 12, 54283956: 54283956
25 HNRNPA1 NM_002136.3(HNRNPA1): c.898C> T (p.Arg300Ter) single nucleotide variant Uncertain significance rs483353037 GRCh37 Chromosome 12, 54677742: 54677742
26 HNRNPA1 NM_002136.3(HNRNPA1): c.898C> T (p.Arg300Ter) single nucleotide variant Uncertain significance rs483353037 GRCh38 Chromosome 12, 54283958: 54283958
27 HNRNPA1 NM_002136.3(HNRNPA1): c.901A> G (p.Asn301Asp) single nucleotide variant Likely pathogenic rs483353039 GRCh37 Chromosome 12, 54677745: 54677745
28 HNRNPA1 NM_002136.3(HNRNPA1): c.901A> G (p.Asn301Asp) single nucleotide variant Likely pathogenic rs483353039 GRCh38 Chromosome 12, 54283961: 54283961
29 HNRNPA1 NM_002136.3(HNRNPA1): c.902A> G (p.Asn301Ser) single nucleotide variant Likely pathogenic rs483353038 GRCh37 Chromosome 12, 54677746: 54677746
30 HNRNPA1 NM_002136.3(HNRNPA1): c.902A> G (p.Asn301Ser) single nucleotide variant Likely pathogenic rs483353038 GRCh38 Chromosome 12, 54283962: 54283962
31 HNRNPA1 NM_002136.3(HNRNPA1): c.922T> G (p.Ser308Ala) single nucleotide variant Likely benign rs483353040 GRCh37 Chromosome 12, 54678056: 54678056
32 HNRNPA1 NM_002136.3(HNRNPA1): c.922T> G (p.Ser308Ala) single nucleotide variant Likely benign rs483353040 GRCh38 Chromosome 12, 54284272: 54284272
33 HNRNPA1 NM_002136.3(HNRNPA1): c.941A> G (p.Tyr314Cys) single nucleotide variant Likely benign rs483353041 GRCh37 Chromosome 12, 54678075: 54678075
34 HNRNPA1 NM_002136.3(HNRNPA1): c.941A> G (p.Tyr314Cys) single nucleotide variant Likely benign rs483353041 GRCh38 Chromosome 12, 54284291: 54284291
35 HNRNPA1 NM_002136.3(HNRNPA1): c.950G> A (p.Gly317Asp) single nucleotide variant Likely benign rs483353042 GRCh38 Chromosome 12, 54284300: 54284300
36 HNRNPA1 NM_002136.3(HNRNPA1): c.950G> A (p.Gly317Asp) single nucleotide variant Likely benign rs483353042 GRCh37 Chromosome 12, 54678084: 54678084
37 HNRNPA1 NM_002136.3(HNRNPA1): c.958T> C (p.Phe320Leu) single nucleotide variant Likely benign rs483353043 GRCh37 Chromosome 12, 54678092: 54678092
38 HNRNPA1 NM_002136.3(HNRNPA1): c.958T> C (p.Phe320Leu) single nucleotide variant Likely benign rs483353043 GRCh38 Chromosome 12, 54284308: 54284308

Expression for Secondary Progressive Multiple Sclerosis

Search GEO for disease gene expression data for Secondary Progressive Multiple Sclerosis.

Pathways for Secondary Progressive Multiple Sclerosis

Pathways related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.53 CCL2 CCR3 CCR5 CD40LG CXCL10 CXCR3
2
Show member pathways
13.3 CCL2 CCR3 CCR5 CD40LG CXCL10 CXCR3
3
Show member pathways
13.17 CCL2 CCR3 CCR5 CD40LG CXCL10 CXCR3
4
Show member pathways
13.12 CCL2 CCR5 CD40LG CXCL10 IFNB1 IFNG
5
Show member pathways
12.98 CCL2 CXCL10 IFNB1 IFNG IL10
6
Show member pathways
12.85 CCL2 CCR3 CCR5 IFNB1 MMP9
7
Show member pathways
12.78 CCL2 CCR3 CCR5 CXCL10 CXCR3
8 12.48 ENO2 MBP S100B SLC1A3
9
Show member pathways
12.46 CCR5 CD40LG IFNG IL10
10 12.44 CCL2 CD40LG CXCL10 IFNG IL10
11
Show member pathways
12.3 CCR5 IFNB1 IFNG IL10
12
Show member pathways
12.23 CCL2 CXCL10 IFNG MMP9
13
Show member pathways
12.15 CCR5 CD40LG IFNG IL10
14
Show member pathways
12.04 CCL2 CCR3 CCR5 CXCL10 CXCR3 MMP9
15 11.98 CCL2 IFNG MMP9
16 11.88 CCR3 IFNG IL10
17 11.87 CCL2 IL10 MMP9
18 11.78 CCL2 CXCL10 IFNB1 MMP9
19 11.74 CCR5 IFNB1 IFNG IL10
20 11.73 CCL2 CXCL10 IFNG MBP MMP9
21 11.7 CXCR3 IFNG IL10
22 11.66 IFNB1 IFNG IL10
23
Show member pathways
11.62 CCL2 CCR3 CCR5 CXCL10 CXCR3
24 11.57 CCL2 CCR3 MMP9
25
Show member pathways
11.56 CD40LG IFNG MMP9
26 11.36 CCL2 CCR5 CXCL10 IL10
27 11.31 CCL2 CD40LG IFNG IL10
28 11.29 CXCL10 IFNB1 IFNG
29 11.19 CCL2 CD40LG MMP9
30 11.12 IFNB1 IFNG IL10
31 11.1 CCL2 CD40LG CXCL10 IL10
32 10.87 CCL2 CXCL10 IFNG IL10 MMP9
33 10.65 CCL2 CCR3 IFNG MMP9

GO Terms for Secondary Progressive Multiple Sclerosis

Cellular components related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 CCL2 CD40LG CXCL10 IFNB1 IFNG IL10
2 cell surface GO:0009986 9.55 CCR5 CD40LG CXCR3 MBP SLC1A3
3 external side of plasma membrane GO:0009897 9.35 CCR3 CCR5 CD40LG CXCL10 CXCR3
4 extracellular space GO:0005615 9.28 CCL2 CD40LG CXCL10 ENO2 IFNB1 IFNG

Biological processes related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.91 CCL2 CD40LG CXCL10 IFNB1 IFNG IL10
2 cytokine-mediated signaling pathway GO:0019221 9.85 CCL2 CCR5 CXCL10 IFNB1 IL10 MMP9
3 chemotaxis GO:0006935 9.8 CCL2 CCR3 CCR5 CXCL10 CXCR3
4 cell surface receptor signaling pathway GO:0007166 9.8 CCL2 CCR5 CXCL10 CXCR3 IFNB1 IFNG
5 cellular response to lipopolysaccharide GO:0071222 9.78 CCL2 CCR5 CXCL10 IL10
6 response to virus GO:0009615 9.73 CXCL10 IFNB1 IFNG
7 calcium-mediated signaling GO:0019722 9.7 CCR3 CCR5 CXCR3
8 inflammatory response GO:0006954 9.7 CCL2 CCR3 CCR5 CD40LG CXCL10 CXCR3
9 B cell differentiation GO:0030183 9.69 CD40LG IFNB1 IL10
10 humoral immune response GO:0006959 9.67 CCL2 IFNB1 IFNG
11 cell chemotaxis GO:0060326 9.65 CCL2 CCR3 CCR5 CXCL10 CXCR3
12 B cell proliferation GO:0042100 9.63 CD40LG IFNB1 IL10
13 positive regulation of synaptic transmission GO:0050806 9.58 S100B SLC1A3
14 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.57 IFNB1 IFNG
15 T cell chemotaxis GO:0010818 9.55 CXCL10 CXCR3
16 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.54 IL10 MBP
17 chemokine-mediated signaling pathway GO:0070098 9.35 CCL2 CCR3 CCR5 CXCL10 CXCR3
18 immune response GO:0006955 9.28 CCL2 CCR3 CCR5 CD40LG CXCL10 CXCR3

Molecular functions related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine binding GO:0019956 9.5 CCR3 CCR5 CXCR3
2 C-C chemokine binding GO:0019957 9.43 CCR3 CCR5 CXCR3
3 C-C chemokine receptor activity GO:0016493 9.33 CCR3 CCR5 CXCR3
4 chemokine receptor activity GO:0004950 9.13 CCR3 CCR5 CXCR3
5 cytokine activity GO:0005125 9.1 CCL2 CD40LG CXCL10 IFNB1 IFNG IL10

Sources for Secondary Progressive Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....